The a2 Milk Company provided a recovery update on its China infant milk formula business and guided for mid single-digit revenue growth in FY27, though the path to normalcy remains uneven. The company reported that China label offtake has recovered to approximately 50% of pre-supply chain disruption levels as of November, up from 40% in August, indicating a gradual stabilization following the product shortages that plagued the second half of FY26.
Management expects total IMF sales to be broadly similar to FY26 levels, suggesting the category will not return to growth until FY28 at the earliest. The company attributes the gradual recovery to recent launches of two new China label products and an updated a2 Platinum offering, supported by increased marketing spend particularly in the first half of FY27.
What matters most for investors is the heavily skewed earnings trajectory. Management expects group revenue and EBITDA to be materially weighted to the second half of FY27, with 1H27 revenue expected to be slightly down on 1H26 and underlying EBITDA margins in the first half materially depressed. For the full year, the company guides underlying EBITDA margin at approximately 15%, with this metric supported by contributions from product innovation, new markets, and continued momentum in other nutritionals and liquid milk categories outside IMF.
The a2 Pōkeno transition remains on track, with one-off transformation costs now expected to be approximately 15 million NZD in FY27, including 5 million in integration costs and 10 million related to the a2 Platinum supply chain and in-market transition. Management has flagged that no further transformation costs are expected in FY28, providing visibility on the cost trajectory beyond the current year. Capital expenditure is guided at approximately 70 million NZD, while cash conversion is expected to be in the 70% to 80% range.
Currency movements present an additional layer of complexity. The New Zealand dollar has devalued since the previous August outlook, which management expects to increase both group revenue and expenses at prevailing rates. However, the net earnings benefit from this currency effect is expected to be offset by hedge losses, limiting upside from foreign exchange movements.
A rules-based approach to leveraged ETFs
See how our quantitative strategy works and who it suits.
Explore the strategyBecome an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CARThe key variables for investor attention over the coming quarters center on the pace of China IMF recovery, the effectiveness of marketing investments in the first half, and the successful execution of the a2 Pōkeno transition. Management has provided a wide range of scenarios depending on the rate of recovery in IMF, noting risks spanning macroeconomic conditions, competitive intensity, supply chain factors, geopolitical developments, and regulatory changes. This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About The a2 Milk Company Limited (ASX: A2M)
The a2 Milk Company Limited is a dairy nutritionals company that sells A2-type protein branded milk and related products, including infant milk formula and other dairy products. The company operates across Australia, New Zealand, China, rest of Asia, and the United States, manufacturing and selling nutritional products and providing licensing services under the a2 Milk and a2 Platinum brands.
Become an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CAR